GenSight Biologics to Attend Upcoming Investor Conferences
Paris, France, April 19, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the following investor conferences:
5th Annual ARM Cell & Gene Investor Day
April 27, 2017 – Boston, MA
Bernard Gilly, Chief Executive Officer, will present on April 27, 2017, at 4:45pm EST, at The State Room.
Deutsche Bank 42nd Annual Health Care Conference
May 3-4, 2017 – Boston, MA
Bernard Gilly, Chief Executive Officer, will present on May 4, 2017, at 9:20am EST, at the InterContinental Boston Hotel.
Please find full PDF press release attached gensight_biologics_pr_2017_nanos_20170328
Contacts
| GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20 |
NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55 |
Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017 |
Source: Gensight
